Antu Biotech (603658): The 24Q3 performance is in line with expectations, and the impact of DRGS2.0 is gradually being implemented

Southwest SecuritiesOct 31, 2024 00:00

Antu Biotech (603658): Controlling shareholders' increase in holdings and company buybacks highlight the company's confidence in the future

sealand securitiesOct 29, 2024 15:06

Antu Biotech (603658): Performance slightly below expectations, still optimistic about future growth

Galaxy SecuritiesOct 27, 2024 00:00

Antu Biotech (603658): Performance is steady and improving under pressure from many parties, and concerns about inflection point opportunities after the policy is cleared

zhongtai SecuritiesOct 27, 2024 00:00

Antu Biotech (603658): Short-term performance is under pressure, optimistic about subsequent recovery

htscOct 26, 2024 00:00

Antu Biotech (603658): Increased R&D investment boosts the company's medium- to long-term development

central chinaSep 5, 2024 20:31

Antu Biotech (603658) 2024 Interim Report Review: Overall performance is growing steadily, maintaining a high growth rate overseas

Aug 27, 2024 00:00

Antu Biotech (603658): Short-term performance is pressured to maintain steady growth in the light emitting business

Aug 23, 2024 16:01

Antu Biotech (603658): Overall performance is stable and R&D investment continues to increase

Aug 23, 2024 16:01

Antu Biotech (603658): Performance is in line with expectations, product structure optimization brings improved profitability

Aug 23, 2024 00:00

Antu Biotech (603658): Steady overall management and increased R&D to help long-term growth

Aug 22, 2024 07:56

Antu Biotech (603658): Q2 profit slightly lower than expected, R&D investment focused on the future

Aug 22, 2024 00:00

Antu Biotech (603658): The performance is in line with expectations, and the hospital is optimistic that the installation will drive growth due to the recovery of the hospital

Aug 21, 2024 16:36

Antu Biotech (603658): Growth is steady under multiple pressures, installed capacity accelerates, and the trend of luminescence is expected to improve in the second half of the year

Aug 20, 2024 00:00

Antu Biotech (603658): The 24Q1 profit growth rate exceeded expectations, and the regular business grew steadily

May 27, 2024 16:01

Antu Biotech (603658): Rapid overseas growth, profit levels have increased

Apr 26, 2024 17:26

Antu Biotech (603658) Review: Regular business growth is steady, new products are being developed at an accelerated pace

Apr 24, 2024 16:11

Antu Biotech (603658): Regular business is growing steadily, and profit levels are improving

Apr 24, 2024 07:11

Antu Biotech (603658): The light emitting business will grow steadily in 2023, and profitability will increase steadily

Apr 23, 2024 07:51

Huaan Securities released a research report on April 22 stating that it gave Antu Biotech (603658.SH) a purchase rating. The main reasons for the rating include: 1) the light emitting business continued to grow steadily, with a growth rate of about 24.88%

Zhitong FinanceApr 22, 2024 21:47